Impella Ins & Outs. CarVasz November :45 12:15

Similar documents
Ray Matthews MD Professor of Clinical Medicine Chief of Cardiology University of Southern California

Mechanics of Cath Lab Support Devices

Mechanics of Cath Lab Support Devices

Circulatory Support: From IABP to LVAD

Rationale for Left Ventricular Support During Percutaneous Coronary Intervention

The Role of Mechanical Circulatory Support in Cardiogenic Shock: When to Utilize

Management of Acute Shock and Right Ventricular Failure

Mechanical Cardiac Support in Acute Heart Failure. Michael Felker, MD, MHS Associate Professor of Medicine Director of Heart Failure Research

Ventricular Assisting Devices in the Cathlab. Unrestricted

Who is the high risk patient?

Bridging With Percutaneous Devices: Tandem Heart and Impella

Percutaneous Mechanical Circulatory Support Devices

Cath Lab Essentials : LV Assist Devices for Hemodynamic Support (IABP, Impella, Tandem Heart, ECMO)

Rationale for Prophylactic Support During Percutaneous Coronary Intervention

UNIVERSITY OF UTAH HEALTH CARE HOSPITALS AND CLINICS

8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes

Intraaortic Balloon Counterpulsation- Supportive Data for a Role in Cardiogenic Shock ( Be Still My Friend )

Introduction to Acute Mechanical Circulatory Support

Percutaneous mechanical circulatory support for treatment and prevention of hemodynamic instability Engström, A.E.

ΑΙΤΙΑ ΕΙΣΑΓΩΓΗΣ ΓΙΑ ΝΟΣΗΛΕΙΑ ΑΝΔΡΑΣ

Assist Devices in STEMI- Intra-aortic Balloon Pump

Case - Advanced HF and Shock (INTERMACS 1)

Understanding the Pediatric Ventricular Assist Device

Rhondalyn C. McLean. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume VII, A. Study Purpose and Rationale

How to do Primary Angioplasty. - Patients with Cardiogenic Shock

DECLARATION OF CONFLICT OF INTEREST

Matching Patient and Pump in the New Era of Percutaneous Mechanical Circulatory Support

ST-Elevation Myocardial Infarction & Cardiogenic Shock. - What Should We Do?

Echo assessment of patients with an ECMO device

High Risk PCI for Heart Failure

Which mechanical assistance for cardiogenic shock?

Mechanical circulatory support in cardiogenic shock The Cardiologist s view ACCA Masterclass 2017

เอกราช อร ยะช ยพาณ ชย

Impedance Cardiography (ICG) Method, Technology and Validity

ECMO as a bridge to durable LVAD therapy. Jonathan Haft, MD Department of Cardiac Surgery University of Michigan

Mechanical Support in the Failing Fontan-Kreutzer

Acute Myocardial Infarction Complicated by Cardiogenic Shock

Cardiogenic Shock Protocol

The majority of patients with cardiomyopathy

TREATMENT OF HIGHER RISK PATIENTS INTRODUCTION TO PROTECTED PCI WITH IMPELLA. IMP v4

Acute Mechanical Circulatory Support Right Ventricular Support Devices

A case of post myocardial infarction ventricular septal rupture CHRISTOFOROS KOBOROZOS, MD

Ted Feldman, M.D., MSCAI FACC FESC

Counterpulsation. John N. Nanas, MD, PhD. Professor and Head, 3 rd Cardiology Dept, University of Athens, Athens, Greece

Percutaneous Mechanical Circulatory Support for Cardiogenic Shock. 24 th Annual San Diego Heart Failure Symposium Ryan R Reeves, MD FSCAI

Recovering Hearts. Saving Lives.

Antonio Colombo. Centro Cuore Columbus and S. Raffaele Scientific Institute, Milan, Italy. Miracor Symposium. Speaker: 15. Parigi: May 16-19, 2017

Cardiogenic Shock. Dr. JPS Henriques. Academic Medical Center University of Amsterdam The Netherlands

Management of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist

Right Ventricular Failure: Prediction, Prevention and Treatment

The World s Smallest Heart Pump

Management of High-Risk Coronary Artery Disease

2018 TCT Investor Update

Left Ventricular Assist Devices (LVADs): Overview and Future Directions

Guideline compliance, utilization trends

Update on Mechanical Circulatory Support. AATS May 5, 2010 Toronto, ON Canada

Hardware in the Chest - From VADs to Valves

Ventricular Assist Devices for Permanent Therapy: Current Status and Future

Mechanical Circulatory Support (MCS): What Every Pharmacist Needs to Know!

Number: Policy *Please see amendment for Pennsylvania Medicaid at the end. Last Review 03/23/2017 Effective: 03/25/2003 Next Review: 07/26/2018

Further devices to treat heart failure

IABP Timing & Fidelity. Pocket Reference Guide

Extra Corporeal Life Support for Acute Heart failure

Edwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved

MEDICAL POLICY Ventricular Assist Devices

Mechanical Cardiac Support and Cardiac Transplant: The Role for Echocardiography

ONTARIO HEALTH TECHNOLOGY ASSESSMENT SERIES

Low cardiac output & Mechanical Support นายแพทย อรรถภ ม ส ศ ภอรรถ ศ ลยศาสตร ห วใจและทรวงอก โรงพยาบาล ราชว ถ

Section 6 Intra Aortic Balloon Pump

Cardiac Interventions

Name of Policy: Ventricular Assist Devices and Total Artificial Hearts

Planned, Short-Term RVAD During Durable LVAD Implant: Indications and Management

STATE OF OKLAHOMA 2014 EMERGENCY MEDICAL SERVICES PROTOCOLS

A National Cardiogenic Shock Initiative (CSI):

Echo in Heart Failure

Conflict of Interest Slide

Cardiogenic Shock in Acute MI

The number of patients in the United States with

HEARTWARE HVAD WAVEFORM APP INSTRUCTIONS

Device Therapy for Heart Failure

Coronary angiography and PCI

Ventricular Assist Devices (VADs) and Percutaneous Cardiac Support Systems

Implantable Ventricular Assist Devices and Total Artificial Hearts

Outcomes for 15,259 US Patients With Acute MI Cardiogenic Shock (AMICS) Supported With Impella

headline a Protected PCI Program: Treating the Most Complex Patients

Impella Versus Intra-Aortic Balloon Pump For Treatment Of Cardiogenic Shock: A Meta-Analysis of Randomized Controlled Trials

Total Artificial Hearts and Implantable Ventricular Assist Devices

National Imaging Associates, Inc. Clinical guidelines CARDIAC CATHETERIZATION -LEFT HEART CATHETERIZATION. Original Date: October 2015 Page 1 of 5

Embolic Protection Devices for Transcatheter Aortic Valve Replacement

FOCUS CONFERENCE 2018

Acute heart failure: ECMO Cardiology & Vascular Medicine 2012

Surgical Options for Temporary MCS

CLINICAL DOSSIER Protected PCI

Left Ventricular Assist Devices LVAD. North Country EMS Program Agency 3/21/12

Relax and Learn At the Farm 2012

3/1/2017. Heart Failure is a major driver of morbidity and mortality in the US 1-7

Technique. Technique. Technique. Monitoring 1. Local anesthetic? Aseptic technique Hyper-extend (if radial)

Accepted Manuscript. Improving Survival in Cardiogenic shock: Is Impella the Answer?,, James J Glazier MD, Amir Kaki MD S (18)

CentriMag Ventricular Assist System (VAS): Patient & Device Management Guidelines

Case Report Rapid Switch from Intra-Aortic Balloon Pumping to Percutaneous Cardiopulmonary Support Using Perclose ProGlide

Transcription:

Impella Ins & Outs CarVasz November 21 2014 10:45 12:15 Nicolas M. Van Mieghem, MD, PhD, FESC Clinical Director of Interventional Cardiology Thoraxcenter, Erasmus MC Rotterdam

Background IABP is widely used for LV support in high-risk PCI & cardiogenic shock The increase in cardiac output by IABP is limited Measurable effects on clinical outcome is scarce

What we need Assist Device should be safe User-friendly Effective LV support Measurable (clinical) benefit

LV Support in EP? Ventricular Tachycardia & EP-Ablation High Risk for Hemodynamic Instability Complex congenital heart disease (Fontan, ) Poor LV function Ischemic Non-ischemic LV support to overcome BP drop while inducing & ablating VT

IMPELLA

Impella CP 14 Fr Cannula 4.66mm 5 Strut Inlet Cage Optimized Impeller Up to 4L/min continuous flow

Impella Principle

8 PROTECT II Trial Design Patients Requiring Prophylactic Hemodynamic Support During Non-Emergent High Risk PCI on Unprotected LM/Last Patent Conduit and LVEF 35% OR 3 Vessel Disease and LVEF 30% IABP + PCI R 1:1 IMPELLA 2.5 + PCI Primary Endpoint = 30-day Composite MAE* rate Follow-up of the Composite MAE* rate at 90 days

Hemodynamic Support Effectiveness Impella 2.5 vs. IABP Cardiac Power Output Maximal Decrease in CPO on device Support from Baseline IABP Impella N=138 N=141-4.2 ± 24 p=0.001-14.2 ± 27 CPO data available only for 279 patients (N=138 IABP and N=141 Impella) CPO= Cardiac Power Output = Cardiac Output x Mean Arterial Pressure x 0.0022 (Fincke R, Hochman J et al JACC 2004; 44:340-348) 9

Learning curve - Impella 2.5 vs. IABP Per Protocol Population 90day Outcome (N=423) IABP IMPELLA N=82 N=82 N=63 N=63 N=65 N=68 10

Impella 2.5 and CP Mean Flow Rate (L/min) Impella 2.5 2.3-2.5 Impella CP > 1 L/min additional Flow Catheter Size 9 Fr 9 Fr Pump Size 12 Fr 14 Fr Insertion Method Guidewire Placement Measurement Cannula Geometry Percutaneous via 13 Fr or 14 Fr Introducer Sheath 0.018 Silicone Wire Fluid-filled Pressure Lumen Curved, Pigtail Percutaneous via 14 Fr Introducer Sheath 0.018 PTFE Wire Fluid-filled Pressure Lumen Curved, Pigtail RPM 51,000 46,000

VT Ablation with Impella or not Miller et al. JACC 2011;58:1363-71

Impella in VT Ablation

Impella in VT Ablation

15 Heart Pumps and Hemolysis? Heart Pumps apply shear forces to red blood cells that if strong enough can damage cell structure Shear forces result from differences in blood velocity (i.e. force) from one side of RBC to the other Shear forces in a heart pump are strongest in regions of high blood velocity differences and small flow channels Shear Force Cannula Wall / Fixed Structure Speed low due to dragging along the wall Hgb Hgb Hgb Speed high away from wall Hgb Shear forces pull apart or distort cell membrane and can cause rupture

Hemolysis with Impella and Other Heart Pumps in Bench Testing? 16 1 2 2 1 1 1 CentriMag/Industry standard data Levitronix Website 2 FDA Comparative Bench Test Data for Impella 2.5 510(k) Clearance

Thoratec PHP

HeartMate PHP Low-profile Designed to provide high forward flow at low RPMs to unload the LV and perfuse end organs Designed to deliver 4-5 lpm average flow Cannula Outlet Impeller Coated Cannula Cannula Inlet Collapsible elastomeric impeller within expandable nitinol cannula 13F insertion profile Expands to 24F when unsheathed Insertion Sequence

HeartMate PHP

Thoratec PHP Pivotal CE Mark study kick-off Q3 2014 Up to 50 patients undergoing high-risk PCI at up to 10 sites in Europe and South America Primary performance endpoint: Freedom from hemodynamic compromise during PCI Primary safety endpoint: Composite of major adverse events.

PulseCath ivac 2L

PulseCath Principle 17F catheter across aortic valve is connected to an extracorporeal membrane pump Pulsecath actively aspirates blood from the left ventricle in systole and ejects this blood into the ascending aorta during diastole Pump is compatible with standard IABP console as a driver

PULSECATH ivac 2L

Hemodynamics Pulsecath 100 40 4,0 3,5 3,0 2,5 2,0 1,5 1,0 0,5 0,0 C.O. C.Output Counterpulsation 100 Diastolic Pressure increases 40 MAP increases C.O. increases*

PULSECATH ivac 2L

LV Support & Access Strategy

PULSECATH ivac 2L Large caliber system (17F) Pulsatile LV Support Genuine IABP console Compared to IABP: C.O. X3 LV Support replacement Safety & efficacy Study ongoing in Rotterdam

In Conclusion LV support is valuable in particular clinical settings Powerful devices are entering the clinical field LV support may also serve complex EP procedures